EGFR and glioblastoma: Consistent with these results, we found that treatment with nimotuzumab and radiation enhanced the inhibition of EGFR-signalling activation, supporting a notion that the inhibition of ERK-mediated signalling is related to radiation response in vivo in GBM (Xia et al, 1995).